Overview

Tech Summary

Promoter Holding

Posts

BIOCON

201234567890012345678960123456789.3012345678950123456789
+4.75 (+2.36%)
The current prices are delayed.Login/Sign Up to see live prices.
Previous Close: 201.6
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
202.3
Today's high
208.2
52 week low
191.55
52 week high
232.7
Volume
3884594
About
Tech Summary
DMA(12)
₹283.15
DMA(50)
₹278.84
DMA(100)
₹295.28
DMA(200)
₹319.52
Fund Summary
Market Cap
₹24774.38 Cr.
Enterprise Value
₹27930.88 Cr.
No. of Shares
120.06
P/E
63.83
RoE
9.83
Debt/Equity
0.6
Valuations
PE Chart
100200300400500
PB Chart
2.53.03.54.04.5
Promoter Holdings
Public : 16.31%
FII : 14.42%
DII : 8.63%
Promoter : 60.64%
Others : 0%
Charts
Debt/Equity
0.400.450.500.550.60
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
ROE vs ROCE
81012141618
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
ROE
ROCE
Revenue vs Profitability (1000Cr.)
2468
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
Revenue
Profit
Margins(%)
1015202530
Mar, 2019Mar, 2020Mar, 2021Mar, 2022
Net Margin
Gross Margin
About
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Stock Sentiments
92% Bullish
8% Bearish
90 live trades of Rs. 4,984,656.7
kumargauravpaper
 
Reputation: 0 • 
Yesterday 8:56 PM
BIOCON APR23 210 PE
2300 Qty (S) Trade entered₹0
A
aiwayhi
 
Reputation: 0 • 
Yesterday 8:34 PM
BIOCON APR23 200 PE
2300 Qty (S) Exited₹115
Posts by FrontPage Users
R
Reputation: 930  •  Yesterday 5:40 AM

Sell - 202.5
SL - 204.5
TG- 199.3

If go to up side Buy- 204.5
Chartbusters - chart - 44522302
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 30 6:11 AM
Viatris puts India API business on the block
Viatris puts India API business on the block
However, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the development. The company has been seeking a valuation of $600-700 million (₹5,000 crore) for the API business and hired Jefferies to run the sale process.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 28 7:11 PM
Cyndrella Carvalho on 6 pharma stocks to bet on now
Cyndrella Carvalho on 6 pharma stocks to bet on now
Valuations in the listed API space have experienced huge price corrections, making them appear attractive, according to Cyndrella Carvalho, Vice President - Healthcare/Pharma Lead, Institutional Research, JM Financial. However, Carvalho added that one or two more quarters are needed for supplies to normalize in the API market to give a clearer understanding of the supply-demand scenario.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 27 2:06 PM
F&O Ban: IB Housing Finance, HAL under ban for trade on Monday; Biocon exits
F&O Ban: IB Housing Finance, HAL under ban for trade on Monday; Biocon exits
"The Nifty witnessed an extremely volatile day of trade on Friday. It was consolidating in a narrow range during the first half of the session. However, as the day progressed and especially during the last couple hours of the trading session the Nifty witnessed intense selling pressure which dragged the Nifty lower to close with a cut of 132 points," Jatin Gedia, Technical Research Analyst at Sharekhan by BNP Paribas said.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 24 6:43 PM
Kotak retains 'reduce' rating on Biocon; lowers target price
Kotak retains 'reduce' rating on Biocon; lowers target price
Brokerage firm Kotak Institutional Equities has retained a "reduce" rating on Biocon Ltd (BIOS) and lowered its target price to Rs 210 from Rs 240 earlier.
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 24 2:31 PM
F&O Ban: Biocon, IB Housing Finance, HAL under ban for trade on Friday
F&O Ban: Biocon, IB Housing Finance, HAL under ban for trade on Friday
The Future & Options contracts of any stock enter the ban period when the open interest (OI) on it crosses 95% of the market-wide positions limits or MWPL. The ban on it is reversed only if the open interest falls below 80%.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 23 8:56 PM
Kiran Mazumdar-Shaw to retire from Infosys board; D Sundaram appointed lead Independent Director
Kiran Mazumdar-Shaw to retire from Infosys board; D Sundaram appointed lead Independent Director
Joshi also led the Finacle banking platform business and AI automation portfolio for Infosys. He was also responsible for the companys internal Chief Investment Officer (CIO) function and Infosys Knowledge Institute and held executive responsibility for large deals across the company.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 23 2:16 PM
F&O Ban: Biocon, IB Housing Finance under ban for trade on Thursday
F&O Ban: Biocon, IB Housing Finance under ban for trade on Thursday
"The daily momentum indicator triggered a fresh positive crossover on Wednesday, which is a buy signal. Also, we believe that the pullback is not yet complete and we expect it to continue over the next few trading sessions," Gedia said.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 23 12:51 PM
SGX Nifty down 50 points; here's what changed for market while you were sleeping
SGX Nifty down 50 points; here's what changed for market while you were sleeping
Asian stocks struggled Thursday in the wake of a slump on Wall Street after Treasury Secretary Janet Yellen rattled bank shares and the Federal Reserve pushed back against bets for interest rate cuts this year. Benchmark indexes fell in Japan, South Korea and Australia while a gauge of US-listed Chinese companies fell earlier.
The Economic Times
Comment
Share
Add a comment
Shashwat Jain-display-image
Reputation: 6,406  •  Mar 23 4:46 AM

Hammer in #BIOCON

Time Frame = 1 Day
Chartbusters - chart - 41482989
3 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 22 2:41 PM
F&O Ban: Biocon, IB Housing Finance under ban for trade on Wednesday
F&O Ban: Biocon, IB Housing Finance under ban for trade on Wednesday
"We expect the positive momentum to continue over the next few trading sessions. On the hourly charts we can observe positive divergence along with a positive crossover on the momentum indicator which indicates loss of momentum on the downside and shall provide speed to the current pullback," Gedia said.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 22 2:11 PM
Big Movers on D-St: What should investors do with Biocon, Sterling & Wilson and UTI AMC?
Big Movers on D-St: What should investors do with Biocon, Sterling & Wilson and UTI AMC?
The Relative Strength Index (RSI) is also trading above the 60 mark which is a bullish sign. Volumes are on the rise suggesting that this rally has legs to move up in the short to medium term.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 22 1:01 PM
SGX Nifty trades flat; here's what changed for market while you were sleeping
SGX Nifty trades flat; here's what changed for market while you were sleeping
"We advise investors to remain cautious, as markets are likely to remain volatile ahead of the Fed's meeting outcome on Wednesday late evening. US Feds commentary amidst the ongoing financial crisis would be of key importance and can provide some direction to the markets," said Siddhartha Khemka, Head - Retail Research, Motilal Oswal Financial Services.
The Economic Times
Comment
Share
Add a comment
R
Reputation: 930  •  Mar 22 5:34 AM

Yesterday Sell BIOCON
Sell- 198.5
SL- 202.5
TG 191.5
Chartbusters - chart - 40965069
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 21 2:51 PM
F&O Ban: Biocon, IB Housing Finance under ban for trade on Tuesday; GNFC exits
F&O Ban: Biocon, IB Housing Finance under ban for trade on Tuesday; GNFC exits
“It closed on a negative note though well off the intraday lows indicating buying interest at lower levels. On the hourly charts, we can observe that the momentum indicator has triggered a positive crossover which is a buy signal. Thus, we expect the Nifty to continue with the positive momentum which has started during the second half of Mondays trading session for the next trading session as well,” Gedia said.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 21 12:31 PM
SGX Nifty up 50 points; here's what changed for markets while you were sleeping
SGX Nifty up 50 points; here's what changed for markets while you were sleeping
"The market is now awaiting the outcome of the Fed meeting to see how they will respond to the ongoing crisis, particularly in terms of rate hikes. Investors expect the central bank to raise interest rates by 0–25 basis points," said Vinod Nair, Head of Research at Geojit Financial Services.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 20 4:16 PM
Hot Stocks: Brokerage firms on Godrej Consumer, DLF, Zydus Life and Biocon
Hot Stocks: Brokerage firms on Godrej Consumer, DLF, Zydus Life and Biocon
The stock traded off recently, making short-term valuations much more compelling. The stock has corrected by over 28% on a year-to-date basis compared to the 2.8% fall seen in the S&P BSE Sensex.
The Economic Times
Comment
Share
Add a comment
S
Reputation: 16  •  Mar 18 3:32 AM
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 17 11:01 PM
Sensex  rises! But these  stocks fell 5% or more in Friday's session
Sensex rises! But these stocks fell 5% or more in Friday's session
In the Nifty pack, 37 stocks closed in the green, while 13 stocks ended in the red.
The Economic Times
Comment
Share
Add a comment
A
Reputation: 0  •  Mar 14 5:17 AM
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 11 6:56 PM
Pharma stocks continue to underperform in 2023. Should investors take the bitter pill?
Pharma stocks continue to underperform in 2023. Should investors take the bitter pill?
The Nifty Pharma Index fell about 6% so far this year on a year-to-date basis. The price pressure in US generic market is seen as a key drag for the sector
The Economic Times
Comment
Share
Add a comment
A
Reputation: 160  •  Mar 3 8:26 PM

236-241 looks easy tgts to trade for
230 call @ 5 can be good for 7.6-11 tgt
Chartbusters - chart - 35040706
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Mar 2 6:56 PM
Will HAL make the cut for MSCI index inclusion in the May review?
Will HAL make the cut for MSCI index inclusion in the May review?
Hindustan Aeronautics has an order book position of Rs 84,000 crore and another Rs 50,000 crore worth of orders are in the pipeline. The PSU company, one of the largest aerospace and defence manufacturers in the world, designs and manufactures aircraft, helicopters, power plants, inertial navigation system and other key equipment.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 28 6:01 PM
Bank of Baroda, Biocon among 13 stocks in focus ahead of MSCI rebalancing
Bank of Baroda, Biocon among 13 stocks in focus ahead of MSCI rebalancing
According to Nuvama, Adani Enterprises may see outflows worth $102 million while HCL Tech, Jindal Steel, Shriram Finance will see outflows of $95 million, $19 million and $15 million respectively. On the other hand, weight reduction in ACC will lead to outflows worth $11 million
The Economic Times
Comment
Share
Add a comment
O
Reputation: 32  •  Feb 28 6:00 PM

#BIOCON consolidating from past 75 mins straight
Let's wait for the breakout
Chartbusters - chart - 33561356
Comment
Share
Add a comment
Option Master Intraday-display-image
Reputation: 101,389  •  Feb 28 3:51 PM


🔰 Sell below 226 or can buy 220PE in here.. SL as per your pocket.

Chart is weak already.
Chartbusters - chart - 33426344
Comment
Share
Add a comment
Pitambar Yadav-display-image
Reputation: 6,067  •  Feb 28 7:10 AM

Chart analysis and trade levels for this week
Good for option and Swing trade
Time frame 15min
Huge volume accumulated in the stock from last 2-3 days
Expecting bullish movement continue this week
Above 230
Targets are 234/237.5/242/245/251
Chartbusters - 33313435
Comment
Share
Add a comment
Shashwat Jain-display-image
Reputation: 6,406  •  Feb 28 3:41 AM

Hammer Pattern in #BIOCON

Time Frame = 1 Day
Chartbusters - chart - 33309848
1 Comment
Share
Add a comment
Stock Sangreh-display-image
Reputation: 9,073  •  Feb 27 10:06 PM

Stock gives reversal signs as RSI shows positive divergence and TSI gives positive crossover.
Risk reward is favourable to enter into this stock.
Entry Price: 225-230
SL: 215 (closing basis)
Target: 245/260/275

Disclaimer: I am not SEBI registered. This ......read more
Chartbusters - chart - 33295280
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 27 9:31 PM
‘India’s flagship indices broadly flattish over last 1 yr’ — Statement conceals more than it reveals
‘India’s flagship indices broadly flattish over last 1 yr’ — Statement conceals more than it reveals
Over a fourth of BSE500 companies have fallen more than 30% in the past year and half of the index constituents are down over 30% from their 2-year highs
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 27 7:03 PM
Buy Biocon; target of Rs 266: Sharekhan
Buy Biocon; target of Rs 266: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 266 in its research report dated February 21, 2023.
Moneycontrol
Comment
Share
Add a comment
S
Reputation: 0  •  Feb 27 3:19 AM
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 23 3:56 PM
Buy Biocon, target price Rs 266:  Sharekhan by BNP Paribas
Buy Biocon, target price Rs 266: Sharekhan by BNP Paribas
Biocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 26389.19 Crore) operating in Pharmaceuticals sector.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 23 3:01 AM
Kotak Special Situations Fund invests Rs 1070 crore in Biocon
Kotak Special Situations Fund invests Rs 1070 crore in Biocon
Eshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acquisition financing supports Biocons journey of becoming a world leading, fully integrated biosimilars enterprise.
The Economic Times
Comment
Share
Add a comment
O
Reputation: 32  •  Feb 23 1:40 AM

#BIOCON is nearing at a very very crucial support zone which is tested only once on 23rd September 2019.
This stock is in continuous downfall since May 2022.
In 1st image, one can clearly see the Inverted Cup and Handle formation in a larger Time Frame or this could be the start ......read more
Comment
Share
Add a comment
The Stocks Arena-display-image
Reputation: 6,539  •  Feb 21 2:26 PM

keep an eye on #BIOCON
---------------------------
range breakdown with volume
Chartbusters - chart - 31105881
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 21 11:41 AM
ACC, Kotak Bank among 10 joining FTSE Russell
ACC, Kotak Bank among 10 joining FTSE Russell
The stocks included in the large-cap index are ACC, Kotak Mahindra Bank, Canara Bank, IDBI Bank, YES Bank, Union Bank, Indian Hotels, Jindal Steel & Power, Shriram Finance, Trent, and Tube Investments. One97 Communications, Biocon, Godrej Properties, Jubilant FoodWorks, Piramal Enterprises, and Sona BLW are the six stocks excluded from the large-cap index.
The Economic Times
Comment
Share
Add a comment
Add a comment
G
Reputation: 0  •  Feb 20 3:04 PM

#BIOCON is monthly demand zone price at 226
BIOCON - chart - 30726993
Comment
Share
Add a comment
R
Reputation: 0  •  Feb 19 9:34 PM

#BIOCON is Bullish for swing Trading at least 2 to 3 Days Holding period buying Rs. 230 to 232 to Target 240 to 245...
Bullish RSI Division.
Comment
Share
Add a comment
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 16 5:26 PM
Buy Biocon, target price Rs 365:  JM Financial
Buy Biocon, target price Rs 365: JM Financial
Given the multiple near-term levers, enviable biosimilars pipeline, strengthening of leadership teams, favourable valuation and marquee investors backing, JM strongly believes the company is well poised to turn the tide in its favour.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 16 5:18 PM
Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here’s what analysts say
Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here’s what analysts say
A one-time loss of Rs 271 crore during the quarter, mainly owing to professional fees paid for the acquisition of the global biosimilars business of American company Viatris, triggered the loss
Moneycontrol
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 16 5:11 PM
Buy Biocon, target price Rs 365:  Yes Securities
Buy Biocon, target price Rs 365: Yes Securities
Given the multiple near-term levers, enviable biosimilars pipeline, strengthening of leadership teams, favourable valuation and marquee investors backing, JM strongly believes the company is well poised to turn the tide in its favour.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 16 4:01 PM
Hot Stocks: Brokerages view on steel stocks, Apollo Hospitals, PB Fintech, Biocon and others
Hot Stocks: Brokerages view on steel stocks, Apollo Hospitals, PB Fintech, Biocon and others
JP Morgan on Tata Steel and SAIL said, "Investor sentiment remains bearish on metals, lacking a meaningful demand recovery in China. Either steel prices need a rally or coking coal prices need to fall. Indian steel mills are well positioned".
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 15 7:31 PM
Kiran Mazumdar Shaw on Viatris acquisition, R&D spend & Q3 result
Kiran Mazumdar Shaw on Viatris acquisition, R&D spend & Q3 result
“The highest R&D spends will always happen in biologics because the highest cost of R&D spend is in clinical trials. As we move forward, there are indications that we can shrink the clinical trials to smaller and smaller cohorts as the regulatory agencies and the markets become more mature in terms of biosimilars. We expect the R&D spends to reduce from current levels.”
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 15 3:46 AM
Biocon reports Rs 42 crore net loss in Q3 due to exceptional item
Biocon reports Rs 42 crore net loss in Q3 due to exceptional item
The biggest contribution came from the biosimilars business, which reported a 54% increase in revenues to Rs 1,507 crore. Research Services revenues (Syngene) rose 23% YoY to Rs 786 crore and generics business revenues grew 18% YoY to Rs 718 crore.
The Economic Times
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 15 1:46 AM
Biocon Q3 Results: Firm posts Rs 42 cr loss on one-time exceptional item
Biocon Q3 Results: Firm posts Rs 42 cr loss on one-time exceptional item
The profit was also impacted due to dilution of Biocons stake in Biocon Biologics and Syngene. Net profit for the quarter, excluding an exceptional item, stood at Rs 140 crore
The Economic Times
Comment
Share
Add a comment
 price action trading-display-image
Reputation: 45,007  •  Feb 13 3:05 AM

TRIANGLE PATTERN
TRADE ON BREAKOUT SDIE
Chartbusters - chart - 28772902
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 35,254  •  Feb 11 2:56 PM
MSCI Adds BoB, CG Power in Rejigged India Index
MSCI Adds BoB, CG Power in Rejigged India Index
MSCI has marginally increased the weights of Reliance Industries, HDFC, Infosys, ICICI Bank, and TCS. The other stocks where outflows could be seen due to a reduction in weightage include HCL Technologies ($97 million), Jindal Steel & Power ($19 million), Shriram Finance ($14 million), and ACC ($12 million), according to Nuvama.
The Economic Times
Comment
Share
Add a comment
Load More Posts